MicroPort CardioFlow Medtech Corporation
微创心通医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2160)

VOLUNTARY ANNOUNCEMENT FIRST CLINICAL APPLICATION OF OUR SELF-DEVELOPED TMVR SYSTEM

This announcement is made by MicroPort CardioFlow Medtech Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that the transcatheter mitral valve replacement system ("**TMVR System**") independently developed by the Group was successfully applied by the heart team of Zhongshan Hospital, Fudan University to treat a patient with severe mitral regurgitation on July 18, 2022. The device was implanted in an ideal position and the mitral regurgitation disappeared immediately with no perivalvular leakage or left ventricular outflow tract obstruction ("**LVOTO**"), and the patient recovered well. Our TMVR System is the world's first dry-tissue transcatheter mitral valve replacement system with clinical application, this successful first-in-man ("**FIM**") application marks its entry into the clinical trial phase.

The TMVR System applied the dry tissue technology independently developed by the Group for the first time, which shows better biocompatibility and anti-calcification properties, facilitating preoperative preparation, storage and transportation, and further improving the safety and durability of the prosthetic valves. The system has both transapical and transseptal approaches. The simplicity in its prosthetic valve design greatly reduces the operative difficulty and the LVOTO risk, bringing excellent hemodynamic performance and solving technical issues in transcatheter mitral valve replacement ("**TMVR**") procedures such as prosthetic valve anchoring and fixation.

Mitral regurgitation is one of the most common life-threatening heart valve diseases. TMVR, as a widely discussed interventional treatment for structural heart diseases in recent years, still presents many technical issues in its clinical applications. Based on our deep understanding and exploration of clinical pain points, we have accomplished several breakthroughs in key technologies and independently developed the TMVR System. This successful FIM application of the TMVR System is another important milestone of the Group's comprehensive deployment in the field of structural heart disease. Relying on our solid technical reserves and innovation capabilities in the field of structural heart disease, we will continue to be committed to solving clinical pain points, developing innovative products starting from patient needs, and providing more trustworthy and universal access to state-of-the-art total solutions to treat structural heart diseases.

There is no assurance that the Company will ultimately be able to successfully commercialize the TMVR System. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
MicroPort CardioFlow Medtech Corporation
Luo Qiyi
Chairman

Shanghai, PRC, July 19, 2022

As of the date of this announcement, the executive directors are Mr. Chen Guoming, Mr. Zhao Liang and Ms. Yan Luying, the non-executive directors are Dr. Luo Qiyi, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.